세계의 아스파라기나아제 주사 시장 보고서(2025년)
Asparaginase For Injection Global Market Report 2025
상품코드 : 1750918
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

아스파라기나아제 주사 시장 규모는 향후 수 년간 강력한 성장이 전망 될 예정입니다. 임상시험 건수 증가, 정밀의료에 대한 수요 확대에 기인하고 있습니다. 예측 기간 중에 예상되는 주요 동향으로서는 맞춤형 의료, 화학요법과의 병용 요법, 바이오테크놀러지의 진보, 드러그 딜리버리 시스템의 개선, 정맥주사 제형으로의 전환, 환자 중심의 치료에 대한 주목, 대체 암 치료법의 인기 증가 등이 포함됩니다.

백혈병의 이환율 증가는 향후 몇 년간의 아스파라기나아제 주사 시장의 성장을 견인할 것으로 예측됩니다. 전 세계적으로 백혈병 발생률이 증가하고 있으며, 그 결과 매년 더 많은 사례가 진단되고 있습니다. 이 동향은 암의 전반적인 부담 증가의 일부이며, 백혈병은 다양한 연령층에서 더 자주 확인되고 있습니다. 아스파라기나아제 주사는 백혈병 세포가 스스로 생산할 수 없는 아미노산인 아스파라긴을 고갈시켜 굶주리게 하고 성장을 억제하는 백혈병 치료제입니다. 그 대부분이 성인이라고 예측되고 있습니다. 또한, 이 보고서에서는 AML에 의한 사망자수는 약 1만 1,090명으로 예측되고, 그 대부분은 성인에서 발생하고 있습니다.

맞춤형 의료에 대한 선호도가 높아지면서 아스파라기나아제 주사 시장의 성장이 가속될 것으로 예측됩니다. 맞춤형 의료는 환자 각자의 특성에 맞게 치료와 건강 관리를 결정하는 것입니다. 개인의 유전자 구성을 기반으로 치료법을 맞춤화함으로써 보다 정확하고 효과적인 치료가 가능하므로 맞춤형 의료에 대한 수요가 높아지고 있습니다. 이 접근법은 치료의 처방에서 시행 착오의 과정을 줄이고, 치료 결과를 개선하고, 더 나은 전반적인 환자 관리를 보장합니다. 개인화 의학에 대한 수요 증가는 유전자 재조합 제형과 같은 맞춤형 제형의 개발을 촉진하고 아스파라기나아제 주사 시장에 긍정적인 영향을 미칩니다. 대장균 유래의 효소에 대한 알레르기를 포함한 환자의 과민증에 대응하여 백혈병 치료의 안전성과 효능을 높일 수 있습니다. 예를 들어 미국의 비영리 단체인 맞춤형 의료연합이 2024년 2월 발표한 보고서에 따르면 FDA가 희소질환 환자를 위해 새로 승인한 개인화 치료제는 2022년 6건에서 2023년 16건으로 증가했습니다. 그 결과, 개인화된 의료에 대한 선호도 증가가 아스파라기나아제 주사 시장을 더욱 촉진할 것으로 예측됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 태와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Asparaginase for injection is an enzyme-based medication primarily used to treat acute lymphoblastic leukemia (ALL) and other forms of cancer. It works by depleting asparagine, an amino acid essential for the growth and survival of cancer cells, thereby inhibiting their proliferation. This drug is typically derived from bacteria such as escherichia coli or erwinia chrysanthemi and is administered via injection.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The key therapeutic areas for asparaginase for injection include oncology, hematology, neurology, and autoimmune disorders. It is available in several formulations, including lyophilized powder, injection solution, and concentrated solution, and can be administered through intravenous, intramuscular, or subcutaneous routes. It is distributed via hospital pharmacies, retail pharmacies, and online pharmacies, and is used to treat conditions such as lymphoblastic leukemia, acute myeloid leukemia, and non-Hodgkin's lymphoma.

The asparaginase for injection market research report is one of a series of new reports from The Business Research Company that provides asparaginase for injection market statistics, including asparaginase for injection industry global market size, regional shares, competitors with a asparaginase for injection market share, detailed asparaginase for injection market segments, market trends and opportunities, and any further data you may need to thrive in the asparaginase for injection industry. This asparaginase for injection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The asparaginase for injection market size has grown strongly in recent years. It will grow from$2.07 billion in 2024 to $2.18 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth during the historical period can be attributed to increased healthcare spending, a growing focus on pediatric cancer treatment, significant unmet medical needs, the availability of reimbursements, a higher prevalence of cancer, improved healthcare infrastructure, and greater awareness of rare diseases.

The asparaginase for injection market size is expected to see strong growth in the next few years. It will grow to$2.71 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The projected growth during the forecast period can be attributed to the rising demand for targeted cancer treatments, increased healthcare investments, a surge in pharmaceutical partnerships, a growing elderly population, a higher number of clinical trials, and the expanding demand for precision medicine. Key trends expected in the forecast period include personalized medicine, combination therapies with chemotherapy, advancements in biotechnology, improvements in drug delivery systems, a shift toward intravenous formulations, a focus on patient-centered care, and the growing popularity of alternative cancer treatments.

The increasing incidence of leukemia is expected to drive the growth of the asparaginase for injection market in the coming years. Leukemia is a cancer that originates in the blood-forming tissues, such as the bone marrow, and leads to the uncontrolled production of abnormal white blood cells. The global incidence of leukemia is on the rise, resulting in more cases being diagnosed annually. This trend is part of a broader increase in the overall burden of cancer, with leukemia becoming more frequently identified across different age groups. Asparaginase for injection is a treatment for leukemia that works by depleting asparagine, an amino acid that leukemia cells cannot produce on their own, thereby starving them and inhibiting their growth. For example, in March 2025, a report from the American Cancer Society, a non-profit organization based in the United States, projected that approximately 22,010 people would be diagnosed with acute myeloid leukemia (AML) in the U.S., most of whom would be adults. The report also anticipated around 11,090 deaths from AML, with the majority of these deaths occurring in adults. Therefore, the increasing prevalence of leukemia is expected to fuel the growth of the asparaginase for injection market.

The growing preference for personalized medicine is also anticipated to accelerate the growth of the asparaginase for injection market. Personalized medicine involves tailoring treatment and healthcare decisions to the specific characteristics of each patient. The demand for personalized medicine is rising as it enables more precise and effective treatments by customizing therapies based on an individual's genetic makeup. This approach reduces the trial-and-error process in prescribing treatments, improves treatment outcomes, and ensures better overall patient care. The increased demand for personalized medicine is positively impacting the asparaginase for injection market by driving the development of customized formulations, such as recombinant versions. These tailored options help address patient sensitivities, including allergies to E. coli-derived enzymes, enhancing both the safety and effectiveness of leukemia treatments. For example, a February 2024 report by the Personalized Medicine Coalition, a U.S.-based non-profit organization, revealed that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, up from just six approvals in 2022. As a result, the growing preference for personalized medicine is expected to further propel the asparaginase for injection market.

Leading companies in the asparaginase for injection market are increasingly focusing on developing technologically advanced products, such as recombinant medications, to treat patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). Recombinant medications are drugs made by using genetically engineered organisms to produce therapeutic proteins or hormones that mimic natural human substances. For instance, in July 2023, Jazz Pharmaceuticals, a biopharmaceutical company based in Ireland, received approval from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for JZP458 (recombinant Erwinia asparaginase, or crisantaspase). This treatment was approved as part of a multi-agent chemotherapy regimen for ALL patients who are hypersensitive to E. coli-derived asparaginase, offering an alternative for about 30% of patients who have difficulty with traditional therapies. Clinical trials have shown that JZP458 maintains essential serum asparaginase activity, supporting its role in treatment.

Major players in the asparaginase for injection market are Roche, Merck And Co, Bristol-Myers Squibb, Novartis AG, Takeda Pharmaceuticals, Amgen Inc, Intas Pharmaceuticals Ltd, Baxter International, Jazz Pharmaceuticals, Clinigen Ltd, Admac Lifesciences, Hetero Healthcare, G J Pharmaceuticals LLP, Actiza Pharmaceutical Pvt. Ltd., Taj Pharmaceuticals, Sayre Therapeutics, Aark Pharmaceuticals, Bruck Pharma Pvt Ltd, Zymeth Pharmaceuticals Pvt. Ltd., Haematologica, Aetos Pharma.

North America was the largest region in the asparaginase for injection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in asparaginase for injection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the asparaginase for injection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The asparaginase for injection market consists of sales of pegaspargase, doxorubicin, cyclophosphamide and vincristine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Asparaginase For Injection Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on asparaginase for injection market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for asparaginase for injection ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The asparaginase for injection market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Asparaginase For Injection Market Characteristics

3. Asparaginase For Injection Market Trends And Strategies

4. Asparaginase For Injection Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Asparaginase For Injection Growth Analysis And Strategic Analysis Framework

6. Asparaginase For Injection Market Segmentation

7. Asparaginase For Injection Market Regional And Country Analysis

8. Asia-Pacific Asparaginase For Injection Market

9. China Asparaginase For Injection Market

10. India Asparaginase For Injection Market

11. Japan Asparaginase For Injection Market

12. Australia Asparaginase For Injection Market

13. Indonesia Asparaginase For Injection Market

14. South Korea Asparaginase For Injection Market

15. Western Europe Asparaginase For Injection Market

16. UK Asparaginase For Injection Market

17. Germany Asparaginase For Injection Market

18. France Asparaginase For Injection Market

19. Italy Asparaginase For Injection Market

20. Spain Asparaginase For Injection Market

21. Eastern Europe Asparaginase For Injection Market

22. Russia Asparaginase For Injection Market

23. North America Asparaginase For Injection Market

24. USA Asparaginase For Injection Market

25. Canada Asparaginase For Injection Market

26. South America Asparaginase For Injection Market

27. Brazil Asparaginase For Injection Market

28. Middle East Asparaginase For Injection Market

29. Africa Asparaginase For Injection Market

30. Asparaginase For Injection Market Competitive Landscape And Company Profiles

31. Asparaginase For Injection Market Other Major And Innovative Companies

32. Global Asparaginase For Injection Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Asparaginase For Injection Market

34. Recent Developments In The Asparaginase For Injection Market

35. Asparaginase For Injection Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기